Molecular Approach to Uterine Leiomyosarcoma: LMP2-Deficient Miceas an Animal Model of Spontaneous Uterine Leiomyosarcoma

• Published in: Complexity (New York, N.Y.) Vol. 2011; no. 2011; pp. 1 - 6
• Main Authors: Konishi, Ikuo, Shiozawa, Tanri, Kanai, Yae, Hiraoka, Nobuyoshi, Sano, Kenji, Horiuchi, Akiko, Hayashi, Takuma, Tonegawa, Susumu
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 2011
• ISSN: 1076-2787; 1099-0526
• DOI: 10.1155/2011/476498

Uterine leiomyosarcoma (LMS) develops more often in the muscle tissue layer of the uterine body than in the uterine cervix. The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known. Importantly, a diagnostic-biomarker which distinguishes malignant LMS from benign tumor leiomyoma (LMA) is yet to be established. Accordingly, it is necessary to analyze risk factors associated with uterine LMS, in order to establish a treatment method. LMP2-deficient mice spontaneously develop uterine LMS, with a disease prevalence of ~40% by 14 months of age. We found LMP2 expression to be absent in human LMS, but present in human LMA. Therefore, defective LMP2 expression may be one of the risk factors for LMS. LMP2 is a potential diagnostic-biomarker for uterine LMS, and may be targeted-molecule for a new therapeutic approach.